Thymosin Beta-4: Evidence, Mechanism, Dosing & Legal Status

Thymosin Beta-4 is a small, ubiquitous endogenous peptide whose dominant biochemical job is sequestering monomeric (G-)actin, giving it broad control over cell migration, angiogenesis, anti-inflammation and anti-apoptosis — the molecular toolkit of wound repair.1 Unlike most peptide-community compounds, it has a genuine multi-decade human-trial record built by RegeneRx and its joint ventures. This monograph separates that real human signal from the marketing.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Thymosin Beta-4 is an investigational drug with no FDA-approved formulation for any indication; the TB-500 fragment sold online is a different, smaller molecule, labeled "for research use only," and is not approved for human use. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is Thymosin Beta-4 and how does it work?

Thymosin β4 is a 43-amino-acid (~4.9 kDa) polypeptide, the most abundant member of the β-thymosin family (70–80% of β-thymosins in mammalian tissue) and present in nearly all cells and body fluids, including wound fluid.12 The synthetic clinical form is timbetasin acetate.3

Its core mechanism is actin sequestration. Tβ4 binds monomeric actin and buffers the pool available for filament assembly; profilin-dependent dissociation of the G-actin·Tβ4 complex then liberates actin for polymerization, dynamically coupling the cytoskeleton to lamellipodial protrusion and cell migration.1 That makes it a potent motility factor — active on endothelial cells at roughly 1 ng and keratinocytes at about 10 pg in vitro.2 Distinct regions carry distinct activities: residues 1–4 (the Ac-SDKP tetrapeptide) are anti-inflammatory and antifibrotic; residues 1–15 are anti-apoptotic; residues 17–23 (LKKTETQ) form the actin-binding motif marketed as TB-500; and residues 40–43 relate to post-ischemic cardiac recovery.1 Beyond actin, Tβ4 engages integrin-linked kinase, PI3K/Akt/eNOS, NF-κB suppression, Notch, TGFβ/Smad inhibition and Wnt/β-catenin signaling — and the actin-binding site itself is required for the pro-angiogenic effect.119

Pharmacokinetics come from controlled human work. In the landmark Phase 1 IV study, synthetic Tβ4 showed dose-proportional exposure, an increasing half-life with increasing dose, consistent terminal clearance and no accumulation over 14 days of daily dosing.14 A separate first-in-human study of recombinant human Tβ4 (NL005, 0.05–25 µg/kg) reproduced dose-proportional Cmax/AUC and consistent clearance.15 A precise single half-life figure is not standardized across reports, and oral bioavailability is not a clinical route.

What is the evidence by indication?

Across every indication, Tβ4's strongest and most reproducible finding is safety. Efficacy is the harder claim: the pivotal ocular and dermal randomized trials generally missed their primary endpoints while showing secondary-endpoint signals. The full trial registry is public — for example, the venous-stasis-ulcer study is registered as NCT00832091 on ClinicalTrials.gov.9

The best human data are ocular. The SEER-1 Phase III trial in neurotrophic keratopathy (0.1% RGN-259, 5×/day, 4 weeks) was randomized, double-masked and placebo-controlled but terminated early in this rare disease (18 of a planned 46 enrolled). Its primary endpoint — complete healing of the persistent epithelial defect at Day 29 — was numerically large at 60% versus 12.5% on placebo, yet not statistically significant (Fisher's exact p=0.0656). By Day 43 the difference reached significance (50% versus 0%, p=0.0359), comfort endpoints improved significantly, and no RGN-259 patient recurred.3 A later European Phase 3 (SEER-3) then failed its primary healing endpoint, attributed partly to an unexpectedly high placebo response.4 In dry eye, a Phase 2 trial showed significant improvement in signs and symptoms,5 but the large ARISE-3 Phase 3 (700 patients) missed its co-primary outcomes while pre-specified secondaries — ocular grittiness and pooled staining scores — improved significantly.67

The dermal program tells the same story. Two Phase 2 blinded dose-response trials of RGN-137 gel in stage III/IV pressure ulcers and venous-stasis ulcers met their primary safety objective but did not achieve statistically significant complete closure; the mid-dose (~0.02–0.03%) was most active, and pooled across roughly 143 patients the peptide accelerated healing by nearly a month in those who healed.89 The mechanistic basis is well supported in animal and in-vitro models.13 In epidermolysis bullosa, a matched-pair Phase 2 produced only a single-subject signal — the first enrolled patient healed in the RGN-137 wound but not the placebo wound — far short of population-level proof.101112

What doses appear in the literature?

Reported strictly as information, not a protocol. Ocular trials used a 0.1% preservative-free ophthalmic solution, instilled five times daily for four weeks in the neurotrophic-keratopathy Phase III and four to six times daily across the dry-eye ARISE program.36 Dermal trials used a topical gel at 0.01%, 0.02–0.03% and 0.1%, with the mid-dose most active in dose-response analyses and applied to the wound over roughly twelve weeks.8 Systemic intravenous work (RGN-352, synthetic Tβ4) explored single and 14-day daily doses of 42, 140, 420 and 1,260 mg in Phase 1; the uncompleted Phase 2 planned 450 mg or 1,200 mg started within 30 minutes of PCI balloon deflation.1416 Recombinant Tβ4 (NL005) was dosed 0.05–25 µg/kg IV in a separate Phase 1.15 Clinical formulations are sterile and preservative-free; online research-chemical vials are not the clinical product and have no validated reconstitution standard.

How safe is Thymosin Beta-4?

Tβ4 has been notably well tolerated across routes and trials — its safety record is its most reproducible finding.143 With topical ocular use the most common adverse event was mild ocular pain or stinging on instillation (ARISE-3: 6.6% versus 4.6% placebo), with no serious treatment-related events and no meaningful changes in intraocular pressure, visual acuity or corneal sensitivity.6 Topical dermal use produced no drug-related serious adverse events at any of three doses,8 and intravenous dosing showed no dose-limiting toxicity and no serious adverse events up to 1,260 mg over a 14-day course.14 The dominant theoretical concern is mechanistic: because Tβ4 is pro-angiogenic and pro-migratory and can modulate focal adhesions and invasion in tumor-cell models, there is an unproven theoretical concern about promoting angiogenesis in occult or active malignancy.1920 Pregnancy and lactation are unstudied and should be avoided; no formal contraindications are established because there is no approved product.

What is the FDA and WADA status in 2026?

There is no FDA-approved Thymosin β4 drug for any indication; all human use to date has been investigational under IND (RGN-259 ocular, RGN-137 dermal, RGN-352 IV).273 The compounding picture is unsettled. In September 2023 the FDA moved a large set of peptides — explicitly including the Thymosin β4 fragment (Ac-LKKTET…, i.e., TB-500) — into 503A Category 2 ('significant safety risk — do not compound'), citing immunogenicity, impurities and limited human data.2124 Following litigation and a September 2024 settlement, the FDA removed a dozen peptides — including the Thymosin Beta-4 fragment — from Category 2, but none except GHK-Cu were promoted to Category 1, so they remain not lawfully compoundable pending PCAC review and formal rulemaking.2223 Net 2026 status: regulatory limbo — neither approved nor a clearly compoundable substance.

For athletes the picture is unambiguous. Both Tβ4 and its TB-500 fragment are prohibited at all times — in and out of competition — under WADA category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); some authorities apply the S0/S2 framework to the growth-factor activity, but the substance is banned either way, with multi-year sanctions imposed on athletes including a four-year ban under the 2024 list.25 The U.S. Department of Defense adopts the WADA categories, so it is prohibited for tested military personnel.25 The single biggest consumer-facing distinction is that the widely sold TB-500 is the seven-residue Ac-LKKTETQ fragment, not the full 43-amino-acid peptide — it keeps the actin-binding motif but lacks the Ac-SDKP antifibrotic domain, and it borrows its reputation from the full peptide's trials while having essentially no qualifying human efficacy data of its own.26

Bottom line. Thymosin Beta-4 pairs a real, decades-long human-trial record with excellent reproducible safety and genuinely promising but unproven efficacy — solidly Grade B, never Grade A, because the pivotal randomized trials mostly missed their co-primary endpoints. Cardiac regeneration, the loudest claim, is Grade C in humans. Legally there is no approved product, compounding is unsettled, and both Tβ4 and TB-500 are WADA-prohibited at all times. Regulatory facts here are current as of June 2026 and should be re-verified after the pending PCAC review.